1009620-97-6 Usage
Uses
Used in Organic Synthesis:
Ethyl 5-(chloromethyl)-1,2,4-oxadiazole-3-carboxylate serves as a key intermediate in organic synthesis, particularly for the creation of complex organic molecules. Its reactivity and the presence of the chloromethyl group make it a versatile building block for the synthesis of a wide range of compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, ethyl 5-(chloromethyl)-1,2,4-oxadiazole-3-carboxylate is utilized for the development of new pharmaceuticals. Its potential biological activities and the ability to form various derivatives with pharmacological properties make it a promising candidate for drug discovery and design.
Used in Pharmaceutical Industry:
Ethyl 5-(chloromethyl)-1,2,4-oxadiazole-3-carboxylate is used as a precursor in the pharmaceutical industry for the synthesis of drugs with potential therapeutic applications. Its unique structure and functional groups contribute to the development of innovative medications that address unmet medical needs.
Safety Considerations:
It is crucial to handle ethyl 5-(chloromethyl)-1,2,4-oxadiazole-3-carboxylate with care and to adhere to proper safety procedures when working with it in a laboratory setting. This ensures the safety of researchers and the integrity of the experimental process.
Check Digit Verification of cas no
The CAS Registry Mumber 1009620-97-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,9,6,2 and 0 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1009620-97:
(9*1)+(8*0)+(7*0)+(6*9)+(5*6)+(4*2)+(3*0)+(2*9)+(1*7)=126
126 % 10 = 6
So 1009620-97-6 is a valid CAS Registry Number.
1009620-97-6Relevant articles and documents
HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED
-
Page/Page column 38, (2010/04/03)
The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in in the treatment of diseases where enhanced M3 receptor activation is implicated.
HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS
-
Page/Page column 66, (2008/12/08)
This invention relates to M3 antagonists of formula (I) wherein R2, R4, R5, R6, W, V, A, D, X, t, u and v are as defined herein; pharmaceutical compositions containing them; methods for their preparation; and their use in the treatment of diseases where enhanced M3 receptor activation is implicated.
NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS M3-RECEPTOR MODULATORS
-
Page/Page column 45; 74-75, (2010/11/30)
A compound of formula (I): Formula (I) having M3 receptor- antagonist activity or having both muscarinic receptor antagonist and ss2-agonist activity; a composition comprising such a compound; the use of such a compound in therapy (such as asthma or COPD)
